| Original language | English (US) |
|---|---|
| Pages (from-to) | 669-674 |
| Number of pages | 6 |
| Journal | Journal of Infectious Diseases |
| Volume | 204 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 1 2011 |
ASJC Scopus subject areas
- Immunology and Allergy
- Infectious Diseases
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
The critical need for alternative antiretroviral formulations, and obstacles to their development. / Swindells, Susan; Flexner, Charles; Fletcher, Courtney V.; Jacobson, Jeffrey M.
In: Journal of Infectious Diseases, Vol. 204, No. 5, 01.09.2011, p. 669-674.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - The critical need for alternative antiretroviral formulations, and obstacles to their development
AU - Swindells, Susan
AU - Flexner, Charles
AU - Fletcher, Courtney V.
AU - Jacobson, Jeffrey M.
N1 - Funding Information: This work was supported by the AIDS Clinical Trials Group funded by the National Institute of Allergy and Infectious Diseases (grants U01 AI68636 and AI068634; AI69450 to S. S.; AI069465 to C. F.; and P01 AI074340, UOI AI68636, and UOI AI68632 to C. V. F.); and the National Institute of Drug Abuse (P01 DA028555-01A1 to S. S. and C. V. F.). Funding Information: Potential conflicts of interest: S. S. has received research grants or contracts from or has been a consultant for Abbott Pharmaceuticals, Bavarian Nordic, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer, and Tibotec Therapeutics. C. V. F. has served as an ad hoc consultant to Bristol-Myers Squibb and Merck, Inc, and received honorarium payments for such participation. C. F. has received grant support from GlaxoSmithKline for research unrelated to this manuscript; has served as a consultant to Bristol-Myers Squibb, Boehringer-Ingelheim, GlaxoSmithKline, Merck, Roche, Schering-Plough, and Tibotec; and has received honoraria for presentations at meetings sponsored in part by Abbott Laboratories. J. J. has received research grants from Progenics and Tanox (now Taimed).
PY - 2011/9/1
Y1 - 2011/9/1
UR - http://www.scopus.com/inward/record.url?scp=80051753353&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80051753353&partnerID=8YFLogxK
U2 - 10.1093/infdis/jir370
DO - 10.1093/infdis/jir370
M3 - Article
C2 - 21788451
AN - SCOPUS:80051753353
VL - 204
SP - 669
EP - 674
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 5
ER -